jardiamet
boehringer ingelheim (nz) limited - empagliflozin 12.5mg; ; metformin hydrochloride 500mg; - film coated tablet - 12.5mg/500mg - active: empagliflozin 12.5mg metformin hydrochloride 500mg excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry pink 02b20004 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.
jardiamet
boehringer ingelheim (nz) limited - empagliflozin 12.5mg; ; metformin hydrochloride 850mg; - film coated tablet - 12.5mg/850mg - active: empagliflozin 12.5mg metformin hydrochloride 850mg excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry pink 02b240006 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.
jardiamet
boehringer ingelheim (nz) limited - empagliflozin 5mg; ; metformin hydrochloride 1000mg; - film coated tablet - 5mg/1000mg - active: empagliflozin 5mg metformin hydrochloride 1000mg excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry yellow 02b220012 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.
jardiamet
boehringer ingelheim (nz) limited - empagliflozin 5mg; ; metformin hydrochloride 500mg; - film coated tablet - 5mg/500mg - active: empagliflozin 5mg metformin hydrochloride 500mg excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry yellow 02b220011 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.
jardiamet
boehringer ingelheim (nz) limited - empagliflozin 5mg; ; metformin hydrochloride 850mg; - film coated tablet - 5mg/850mg - active: empagliflozin 5mg metformin hydrochloride 850mg excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry yellow 02b220010 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.
synjardy
boehringer ingelheim - empagliflozin, metformin - diabetes mellitus, type 2 - drugs used in diabetes - synjardy is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients inadequately controlled on their maximally tolerated dose of metformin alone;in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin;in patients already being treated with the combination of empagliflozin and metformin as separate tablets.
jardiance film-coated tablet 25mg
boehringer ingelheim singapore pte. ltd. - empagliflozin - tablet, film coated - 25.00mg - empagliflozin 25.00mg
empiget film coated tablet
getz pharma private limited, pakistan - empagliflozin - film coated tablet - 25 mg
xempa 25 tablets
empagliflozin tablets - tablet - empagliflozin 25 mg/tablet - blood glucose lowering drugs excl. insulins
glyxambi 25mg/5mg film-coated tablet
boehringer ingelheim (philippines), inc.; distributor: boehringer ingelheim (philippines), inc. - empagliflozin , linagliptin - film-coated tablet - 25mg/5mg